Capital Increase / Dilution2026-06-25

AprilBio to issue convertible preferred shares

APR

에이프릴바이오

397030

+0.05

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=2719

Risk-adjusted indicator based on 2719 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Initial conversion price: 40,908 KRW per share
  • • Minimum preferred dividend rate: 1% of par value annually
  • • Lock-up period for new shares: 1 year from electronic registration date

AI Analysis Summary

AprilBio Co.,Ltd. has decided on a paid-in capital increase through the issuance of convertible preferred shares. The initial conversion price is set at 40,908 KRW per share. These new shares will have a minimum annual preferred dividend rate of 1% of their par value and will be cumulative and participating. New shareholders will be subject to a 1-year lock-up period from the electronic registration date, during which conversion rights cannot be exercised. The conversion price is subject to adjustment based on market conditions, including a downward adjustment if the company issues new shares or equity-linked securities at a lower price. The purpose of the capital increase and the specific number of shares or total funding amount are not disclosed in the provided text, making a full assessment of dilution impact difficult. The capital increase is expected to be neutral in the short term, pending further details on the scale and use of funds.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: 주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.